Skip to content

To investigate the impact of psoriasis on cardiovascular comorbidities, particularly atherosclerotic plaque formation.

To investigate the impact of psoriasis on cardiovascular comorbidities, particularly atherosclerotic plaque formation.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125236
Enrollment
Unknown
Registered
2026-05-22
Start date
2026-05-22
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis with atherosclerosis

Interventions

Psoriasis with comorbid patients, biologic-na?ve group:None
Non-psoriasis control group:None
Psoriasis patients with comorbid conditions, biologic-treated group:None

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. age >= 18 years; 2. Presence of atherosclerotic plaques confirmed by imaging examinations and indication for plaque endarterectomy; 3. Willingness to comply with study procedures and participate throughout the entire study process; 4. Provision of a signed and dated informed consent form. 5. Psoriasis patients receiving biologic therapy group: patients with a clinical diagnosis of psoriasis who are currently receiving or have regularly received biologic therapy within the past 3 months (e.g., TNF-a inhibitors, IL-17/IL-23 inhibitors, etc.). 6. Psoriasis patients without biologic therapy group: patients with a clinical diagnosis of psoriasis who have never received biologic therapy; treatment with conventional systemic therapies or topical therapies is permitted. 7. Participants in the non-psoriasis control group are required to have no prior history of psoriasis and no exposure to psoriasis-related systemic treatments.

Exclusion criteria

Exclusion criteria: 1. History or presence of malignancy, autoimmune diseases, or other inflammatory disorders; 2. Presence of acute or chronic active infections; 3. Pregnant or breastfeeding women; 4. Severe organ dysfunction; 5. Individuals unable to understand the study procedures or provide written informed consent.

Design outcomes

Primary

MeasureTime frame
Distribution and functional status of immune cell subsets;

Secondary

MeasureTime frame
laboratory test results;Imaging assessment parameters;Demographic and clinical characteristics;

Countries

China

Contacts

Public ContactXia Li

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

drlixia@126.com+86 21 6437 0045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026